SG11201906765UA - Personalised immunogenic peptide identification platform - Google Patents

Personalised immunogenic peptide identification platform

Info

Publication number
SG11201906765UA
SG11201906765UA SG11201906765UA SG11201906765UA SG11201906765UA SG 11201906765U A SG11201906765U A SG 11201906765UA SG 11201906765U A SG11201906765U A SG 11201906765UA SG 11201906765U A SG11201906765U A SG 11201906765UA SG 11201906765U A SG11201906765U A SG 11201906765UA
Authority
SG
Singapore
Prior art keywords
international
march
methods
personalised
polypeptide
Prior art date
Application number
SG11201906765UA
Inventor
Julianna Lisziewicz
Levente Molnár
Enikő Tőke
József Toth
Orsolya Lorincz
Zsolt Csiszovszki
Eszter Somogyi
Katalin Pántya
Mónika Megyesi
Original Assignee
Treos Bio Zrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61386864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201906765U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP17159242.1A external-priority patent/EP3369431A1/en
Priority claimed from EP17159243.9A external-priority patent/EP3370065A1/en
Priority claimed from GBGB1703809.2A external-priority patent/GB201703809D0/en
Application filed by Treos Bio Zrt filed Critical Treos Bio Zrt
Publication of SG11201906765UA publication Critical patent/SG11201906765UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT 0111111010 0111 °nolo III OH Emmo muoi IIII iflo oimIE (10) International Publication Number WO 2018/158456 Al (51) International Patent Classification: A61K 39/00 (2006.01) GO1N 33/569 (2006.01) G01N 33/50 (2006.01) A61K 39/12 (2006.01) (21) International Application Number: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 17159243.9 17159242.1 1703809.2 PCT/EP2018/055231 02 March 2018 (02.03.2018) English English 03 March 2017 (03.03.2017) EP 03 March 2017 (03.03.2017) EP 09 March 2017 (09.03.2017) GB Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) cc 00 O C (71) Applicant: TREOS BIO ZRT [HU/HU]; Viola utca 2, 8200 Veszprem (HU). (72) Inventors: LISZIEWICZ, Julianna; Szorosi ut 13, 8200 Balatonalmadi (HU). MOLNAR, Levente; Kossuth Lajos u. 20., Felsopakony 2363 (HU). TOKE, Eniko, R.; Kos- suth Lajos u. 20., Felsopakony 2363 (HU). TOTH, Jozsef; Ujkut u. 72, 9012 Gyor (HU). LORINCZ, Orsolya; At- tila u. 27, fszt/13, 1047 Budapest (HU). CSISZOVSZKI, Zsolt; Attila u. 27, fszt/13, 1047 Budapest (HU). SOM- OGYI, Eszter; Borgazda u. 3, 8220 Balatonalmadi (HU). PANTYA, Katalin; Ulloi ut 16/b 2.em. 9/b, Budapest 1085 (HU). MEGYESI, Monika; Tancsics Mihaly u. 63, 3441 Mezokeresztes (HU). (74) Agent: KIMBLIN, Nicola; 14 South Square, Gray's Jim, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: PERSONALISED IMMUNOGENIC PEPTIDE IDENTIFICATION PLATFORM (57) : The disclosure relates to methods of identifying fragments of a polypeptide that are immunogenic for a specific human subject, methods of preparing personalised pharmaceutical compositions comprising such polypeptide fragments, human subject-spe- cific pharmaceutical compositions comprising such polypeptide fragments, and methods of treatment using such compositions. The methods comprise identifying a fragment of the polypeptide that binds to multiple HLA of the subject.
SG11201906765UA 2017-03-03 2018-03-02 Personalised immunogenic peptide identification platform SG11201906765UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP17159242.1A EP3369431A1 (en) 2017-03-03 2017-03-03 Vaccine
EP17159243.9A EP3370065A1 (en) 2017-03-03 2017-03-03 Immunogenic peptides
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
PCT/EP2018/055231 WO2018158456A1 (en) 2017-03-03 2018-03-02 Personalised immunogenic peptide identification platform

Publications (1)

Publication Number Publication Date
SG11201906765UA true SG11201906765UA (en) 2019-08-27

Family

ID=61386864

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201907402SA SG11201907402SA (en) 2017-03-03 2018-03-02 Population-based immunogenic peptide identification platform
SG11201907524UA SG11201907524UA (en) 2017-03-03 2018-03-02 Peptide vaccines
SG11201906765UA SG11201906765UA (en) 2017-03-03 2018-03-02 Personalised immunogenic peptide identification platform

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201907402SA SG11201907402SA (en) 2017-03-03 2018-03-02 Population-based immunogenic peptide identification platform
SG11201907524UA SG11201907524UA (en) 2017-03-03 2018-03-02 Peptide vaccines

Country Status (16)

Country Link
US (9) US10213497B2 (en)
EP (3) EP3589954A1 (en)
JP (4) JP7437939B2 (en)
KR (3) KR20190133177A (en)
CN (3) CN110651188B (en)
AU (3) AU2018226566A1 (en)
BR (3) BR112019018313A2 (en)
CA (3) CA3054861A1 (en)
CL (4) CL2019002534A1 (en)
CO (3) CO2019010524A2 (en)
IL (3) IL268919B2 (en)
MA (3) MA47677A (en)
MX (3) MX2019010461A (en)
SG (3) SG11201907402SA (en)
WO (3) WO2018158457A1 (en)
ZA (2) ZA201904723B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016235388B2 (en) * 2015-03-20 2022-02-03 Children's National Medical Center Generating virus or other antigen-specific T cells from a naive T cell population
SG11201907402SA (en) 2017-03-03 2019-09-27 Treos Bio Zrt Population-based immunogenic peptide identification platform
KR20210086612A (en) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 peptide vaccine
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
US11945850B2 (en) * 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202039535A (en) * 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
KR102159921B1 (en) * 2020-03-24 2020-09-25 주식회사 테라젠바이오 Method for predicting neoantigen using a peptide sequence and hla allele sequence and computer program
JP2023520562A (en) 2020-04-03 2023-05-17 ペップティーシー ヴァクシーンズ リミテッド coronavirus vaccine
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
BR112022012316A2 (en) * 2020-04-20 2022-11-16 NEC Laboratories Europe GmbH A COMPUTER-IMPLEMENTED METHOD OF SELECTING ONE OR MORE AMINO ACID SEQUENCES FOR INCLUSION IN A VACCINE FROM A SET OF PREDICTED IMMUNOGENIC CANDIDATES AMINO ACID SEQUENCES; METHOD OF CREATING A VACCINE; SYSTEM FOR SELECTING ONE OR MORE AMINO ACID SEQUENCES FOR INCLUSION IN A VACCINE FROM A SET OF PREDICTED IMMUNOGENIC CANDIDATES AMINO ACID SEQUENCES; AND; COMPUTER READABLE MEDIUM
CN112048001B (en) * 2020-09-08 2022-04-05 南方科技大学 Tumor neogenesis antigen polypeptide and application thereof
KR102278727B1 (en) * 2020-09-16 2021-07-19 주식회사 테라젠바이오 Method for predicting neoantigen using a peptide sequence and hla class ii allele sequence and computer program
WO2023017768A1 (en) 2021-08-10 2023-02-16 日本電気株式会社 Information processing system and information processing method
TW202322137A (en) 2021-10-04 2023-06-01 日商日本電氣股份有限公司 Management method, management system, and electronic health record system
WO2023059606A1 (en) * 2021-10-06 2023-04-13 Cancervax, Inc. Methods and compositions for cancer treatment
WO2023211024A1 (en) * 2022-04-27 2023-11-02 포항공과대학교 산학협력단 Method for constructing hotspot-derived peptide-nucleic acid hybrid molecules on basis of in vitro selection
CN115785203B (en) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 Lung cancer specific molecular target 10 and application thereof
GB202216453D0 (en) 2022-11-04 2022-12-21 Lisziewicz Julianna Identification of antigens which induce t-cell responses

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
ATE511849T1 (en) 1996-03-11 2011-06-15 Epimmune Inc PEPTIDES WITH INCREASED BINDING AFFINITY FOR AT LEAST THREE HLA-A3-LIKE MOLECULES
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
KR100663319B1 (en) * 1997-04-14 2007-01-02 마이크로메트 에이지 A human antibody specific for the human 17-1A antigen and uses thereof
FR2791895B1 (en) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MXPA05002455A (en) 2002-09-06 2005-06-03 Mannkind Corp Epitope sequences.
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
WO2004092360A2 (en) 2003-04-10 2004-10-28 Chiron Corporation The severe acute respiratory syndrome coronavirus
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
JP4779067B2 (en) 2004-01-20 2011-09-21 愛知県 Epitope peptide recognized by HLA-A2402-restricted Ep-CAM specific CTL and use thereof
CA2566506A1 (en) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
EP1842911A4 (en) 2005-01-25 2008-12-10 Nec Corp Hla-binding peptides, dna fragments encoding the same and recombinant vectors
RU2396088C2 (en) 2005-02-04 2010-08-10 СУРВАК АпС Survivin peptide vaccine
CN100402554C (en) * 2005-02-25 2008-07-16 李玉新 Preparation and use of testes specificity protein 50 human source antibody
FR2891462B1 (en) 2005-09-30 2009-10-16 Commissariat Energie Atomique CD4 + EPITOPES OF SURVIVIN AND THEIR APPLICATIONS
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
US9487574B2 (en) 2006-09-21 2016-11-08 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
WO2008039874A2 (en) 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2042600A1 (en) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications
JP5546448B2 (en) 2008-03-31 2014-07-09 株式会社バイオイミュランス Survivin partial peptides presented on MHC class II molecules and methods of use thereof
DK2119726T5 (en) 2008-05-14 2018-03-26 Immatics Biotechnologies Gmbh Novel and powerful MHC class II peptides derived from survivin and neurocan
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0818065D0 (en) * 2008-10-02 2008-11-05 Cancer Rec Tech Ltd Immunogenic peptides and uses thereof
US20120244145A1 (en) * 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
US20170039314A1 (en) * 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (en) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2015164798A1 (en) 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
AU2015314776A1 (en) 2014-09-14 2017-04-06 Washington University Personalized cancer vaccines and methods therefor
EP3227679A1 (en) * 2014-12-03 2017-10-11 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
JP7236216B2 (en) * 2015-04-23 2023-03-09 ナントミクス，エルエルシー Cancer neoepitopes
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
JP2018532736A (en) * 2015-10-12 2018-11-08 ナントミクス，エルエルシー Systems, compositions, and methods for MSI and neoepitope search to predict susceptibility to checkpoint inhibitors
GB201604755D0 (en) 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
US11684657B2 (en) 2016-10-07 2023-06-27 Board Of Regents, The University Of Texas System HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
TWI796314B (en) 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
SG11201907402SA (en) 2017-03-03 2019-09-27 Treos Bio Zrt Population-based immunogenic peptide identification platform
EP3731876A4 (en) 2017-12-28 2022-04-06 Gritstone bio, Inc. Antigen-binding proteins targeting shared antigens
US20210213066A1 (en) 2018-05-18 2021-07-15 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
EP3796923A4 (en) 2018-05-18 2022-03-09 Children's National Medical Center Improved targeted t-cell therapy
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
KR20210086612A (en) 2018-09-04 2021-07-08 트레오스 바이오 리미티드 peptide vaccine
EP3908293A4 (en) 2019-01-07 2023-01-11 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
US20220062342A1 (en) 2019-01-07 2022-03-03 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
MX2019010460A (en) 2020-01-09
IL268919B1 (en) 2023-06-01
WO2018158457A1 (en) 2018-09-07
ZA201904723B (en) 2024-01-31
US20220031823A1 (en) 2022-02-03
MA47683A (en) 2020-01-08
CA3054871A1 (en) 2018-09-07
IL268917B (en) 2022-12-01
ZA201904725B (en) 2024-01-31
WO2018158455A1 (en) 2018-09-07
MA47677A (en) 2020-01-08
US11213578B2 (en) 2022-01-04
KR20190133177A (en) 2019-12-02
CL2019002534A1 (en) 2020-02-07
CO2019010503A2 (en) 2020-01-17
WO2018158456A1 (en) 2018-09-07
BR112019018307A2 (en) 2020-03-31
AU2018228786A1 (en) 2019-08-01
US10213497B2 (en) 2019-02-26
CO2019010524A2 (en) 2020-01-17
CL2022002836A1 (en) 2023-06-16
CN110651188B (en) 2024-02-02
KR20190134636A (en) 2019-12-04
CN110651189A (en) 2020-01-03
MX2019010461A (en) 2020-01-09
US20180250399A1 (en) 2018-09-06
KR102549625B1 (en) 2023-06-28
US20220111024A1 (en) 2022-04-14
CL2019002532A1 (en) 2020-02-07
US20180264095A1 (en) 2018-09-20
MX2019010459A (en) 2020-01-09
SG11201907402SA (en) 2019-09-27
JP7437939B2 (en) 2024-02-26
CN110621334A (en) 2019-12-27
CO2019010698A2 (en) 2020-01-17
US20220072114A1 (en) 2022-03-10
IL268919B2 (en) 2023-10-01
US11628211B2 (en) 2023-04-18
KR102591136B1 (en) 2023-10-17
BR112019018313A2 (en) 2020-05-19
BR112019018312A2 (en) 2020-03-31
IL268917B2 (en) 2023-04-01
AU2018226566A1 (en) 2019-08-01
CN110651188A (en) 2020-01-03
CA3054861A1 (en) 2018-09-07
SG11201907524UA (en) 2019-09-27
EP3589310A1 (en) 2020-01-08
KR20190133010A (en) 2019-11-29
JP2023051941A (en) 2023-04-11
US11426452B2 (en) 2022-08-30
EP3589951A1 (en) 2020-01-08
JP2020511672A (en) 2020-04-16
JP2020514413A (en) 2020-05-21
US20190240302A1 (en) 2019-08-08
US20220111025A1 (en) 2022-04-14
MA47678A (en) 2021-05-26
JP2020510698A (en) 2020-04-09
AU2018228785A1 (en) 2019-08-01
US20180264094A1 (en) 2018-09-20
IL268920A (en) 2019-10-31
EP3589954A1 (en) 2020-01-08
CA3054866A1 (en) 2018-09-07
IL268919A (en) 2019-10-31
IL268917A (en) 2019-10-31
CL2019002533A1 (en) 2020-02-07
US20230405100A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
SG11201906765UA (en) Personalised immunogenic peptide identification platform
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201806340YA (en) Zika virus vaccine
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201807912SA (en) Vaccine against rsv
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201906958TA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201404836QA (en) Long-acting coagulation factors and methods of producing same
SG11201900021PA (en) Methods and compositions for the treatment of cancer
SG11201901411VA (en) Conditionally active polypeptides and methods of generating them
SG11201907927SA (en) Binding molecules that specifically bind to tau
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201901347UA (en) Compositions and methods for cancer immunotherapy
SG11201909837YA (en) Methods for treating lung disorders
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201900361RA (en) Methods of treating prostate cancer
SG11201909882SA (en) Targeted neoepitope vectors and methods therefor
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201906383WA (en) A layered medical data computer architecture